Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Newly filed 8K

$Adaptimmune Therapeutics (ADAP.US)$ Item 1.01Entry into a Material Definitive Agreement.
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8, 2024 in order to, among other things, resolve and release each party from any and all past, present and future disputes, claims, demands and causes of action, whether known or unknown, related to the Collaboration Agreement in any way. Under the terms of the Agreement, Genentech will pay the Company $12,500,000, and the Collaboration Agreement will be terminated. The Agreement is effective as of September 23, 2024 following which each party to the Agreement is expressly released from any and all past, present and future disputes, claims, demands and causes of action, whether known or unknown, related to the Collaboration Agreement in any way.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
2
+0
2
Translate
Report
3940 Views
Comment
Sign in to post a comment
3285Followers
29Following
49KVisitors
Follow